Cleared Traditional

K974503 - ROCHE AMPLICOR CT/NG TEST FOR NEISSERIA...

K974503 is the FDA 510(k) clearance for ROCHE AMPLICOR CT/NG TEST FOR NEISSERIA... by Roche Molecular Systems, Inc.. It is a Class 2 Microbiology device (product code LSL) cleared through the Traditional 510(k) pathway after a 733-day FDA review.

K974503 · Roche Molecular Systems, Inc. · Microbiology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Dec 1999
Decision
733d
Days
Class 2
Risk

K974503 is an FDA 510(k) clearance for the ROCHE AMPLICOR CT/NG TEST FOR NEISSERIA GONORRHOEAE. Classified as Dna-reagents, Neisseria (product code LSL), Class II - Special Controls.

Submitted by Roche Molecular Systems, Inc. (Branchburg, US). The FDA issued a Cleared decision on December 1, 1999 after a review of 733 days - an unusually long review period, suggesting complex equivalence evaluation.

This device falls under the Microbiology FDA review panel, regulated under 21 CFR 866.3390 - the FDA microbiology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: High-complexity regulatory submission. Elevated predicate reliance profile. The extended review timeline suggests the FDA required additional documentation before confirming substantial equivalence - a pattern common in complex or first-of-kind Microbiology submissions.

View all Roche Molecular Systems, Inc. devices

Submission Details

510(k) Number K974503 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received November 28, 1997
Decision Date December 01, 1999
Days to Decision 733 days
Submission Type Traditional
Review Panel Microbiology (MI)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
631d slower than avg
Panel avg: 102d · This submission: 733d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code LSL Dna-reagents, Neisseria
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 866.3390
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Microbiology devices follow this clearance model.

Regulatory Peers - LSL Dna-reagents, Neisseria

All 35
Devices cleared under the same product code (LSL) and FDA review panel - the closest regulatory comparables to K974503.
TIGRIS DTS AUTOMATED ANALYZER FOR AUTOMATING AMPLIFIED NUCLEIC ACID TEST ASSAYS
K032194 · Gen-Probe, Inc. · Dec 2003
BDPROBETEC ET CT/GC AMPLIFIED DNA ASSAY
K012351 · Becton, Dickinson & CO · Sep 2001
GEN-PROBE APTIMA COMBO 2 ASSAY
K003395 · Gen-Probe, Inc. · May 2001
ROCHE COBAS AMPLICOR CT/NG TEST FOR NEISSERIA GONORRHOEAE
K974342 · Roche Molecular Systems, Inc. · May 1999
LCX NEISSERIA GONORRHOEAE ASSAY
K935833 · Abbott Laboratories · May 1996
GEN-PROBE PACE 2C SYST CHLAMYDIA TRAC/NEISSER GONORR
K940979 · Gen-Probe, Inc. · Oct 1994